cp wire

CP Wire Articles

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China
  • Tislelizumab is a monoclonal antibody PD-1 checkpoint inhibitor
  • BeiGene and Celgene have a global collaboration agreement for the development of  tislelizumab outside of Asia (except... read more
Wed, 07/25/18 - 09:49 am
Finch Therapeutics Expands Microbiome IP Portfolio with Six New Patents
  • Finch has 34 US and Foreign Patents in Its portfolio
  • The Company has 60 patent applications pending

Finch Therapeutics Group... read more

Wed, 07/25/18 - 08:59 am
More Positive Results For Takeda's Alunbrig Acquisition
  • Alunbrig demonstrated statistically superior progression-free survival vs crizotinib in patients with ALK+ NSCLC
  • Alunbrig previously received accelerated approval from the FDA for... read more
Wed, 07/25/18 - 08:49 am
Adaptimmune Completes Transition of Pioneering T-Cell Therapy to GSK – Will Receive $27 Million Payment
  • GSK ‘794 is an engineered T-cell therapy using patient's own cells
  • Ptoential payments to Adaptimmune could be as much as $500 million
  • Adaptimmune as three additional TCR... read more
Tue, 07/24/18 - 10:17 am
Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine
  • At Week 96, 73.1 percent of the treatment group achieved viral suppression
  • Previously reported - at week 48 DOR met its primary efficacy endpoint of non-inferiority compared to DRV+r... read more
Tue, 07/24/18 - 09:55 am

Pages